Search - tctmd.com

Displaying 1 - 17 of 17

Sort: Relevancy | Date

Presentation TCT 2019

DMR: EVEREST II Was a Decade Ago; Have MitraClip Techniques and Outcomes Improved?

Presenter: Stephen Little

September 26, 2019

Presentation TCT 2017

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Presenter: Roxana Mehran, Robert W. Yeh, Sanjay Kaul

October 30, 2017

Presentation

Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation (MR):5-Year results of EVEREST II

Presenter: Ted Feldman

December 21, 2015

Presentation TCT 2015

Five-Year Randomized EVEREST II Results: Where MitraClip Shined (and Where It Didnt)

Presenter: Stephan Baldus, Scott Lim, Ted E. Feldman

October 11, 2015

Presentation TVT 2015

EVEREST II at 5 Years: Lessons Learned and Implications for Future Trials

Presenter: Paul A. Grayburn, Nicole Ibrahim, David L. Brown, Ted Feldman

June 05, 2015

Presentation TVT 2015

EVEREST II 5-Year Report: Beyond the Top-Line Results

Presenter: Antonio Colombo, Gregg W. Stone, Ted Feldman

June 04, 2015

Presentation TCT 2014

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Saibal Kar

September 16, 2014

Presentation TCT 2014

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Ted E. Feldman

September 13, 2014

Presentation TCT 2014

Anatomic Criteria for the MitraClip: Are the Everest Criteria Just a Start?

Presenter: Olaf Franzen, James B. Hermiller Jr, Michael J. Rinaldi, Saibal Kar

September 13, 2014

Presentation TCT 2014

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Presenter: Blase A. Carabello, Allan Schwartz, Charles J. Davidson, Saibal Kar

September 13, 2014

Presentation TCT 2013

TCT-85. Ventricular and Atrial Remodeling after the Percutaneous MitraClip: 4 year Follow-up Data from the EVEREST II Randomized Controlled Trial

Presenter: Atif Qasim

October 29, 2013

Presentation TCT 2013

TCT-89. Percutaneous Leaflet Therapy of Severe Primary Mitral Regurgitation: Totality of Evidence From the EVEREST II Randomized, Continued Access, and High Risk Clinical...

Presenter: Saibal Kar

October 29, 2013

Presentation TCT 2013

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Presenter: Ted Feldman, Elyse Foster, Mansoor Qureshi, Brian Whisenant, John Williams, Donald Glower, Laura Mauri

January 31, 2013

Presentation TCT 2013

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Presenter: Matthew Reynolds, Benjamin Galper, Patricia Apruzzese, Joshua Walczak, Laura Mauri, Ted Feldman, Donald Glower, David Cohen

January 31, 2013

Presentation TCT 2012

Lessons from EVEREST II

Presenter: Ted Feldman

October 24, 2012

Presentation

Acute and 12-Mo Results with Catheter-Based Mitral Valve Leaflet Repair: EVEREST II High Risk Study

Presenter: Patrick L. Whitlow

January 04, 2012

Presentation TCT 2012

EVEREST II High Surgical Risk Cohort: Clinical Benefit by MR Grade in High Surgical Risk Patients One Year Following MitraClip Therapy.

Presenter: Paul Grayburn, Saibal Kar, Ted Feldman, Donald Glower, Elyse Foster, Laura Mauri

January 03, 2012

Advertisement

DMR: EVEREST II Was a Decade Ago; Have MitraClip Techniques and Outcomes Improved?

How to Interpret Noninferiority Trials (eg, ABSORB III, EVEREST II, and Others)

Randomized Comparison of Percutaneous Repair and Surgery for Mitral Regurgitation (MR):5-Year results of EVEREST II

Five-Year Randomized EVEREST II Results: Where MitraClip Shined (and Where It Didnt)

EVEREST II at 5 Years: Lessons Learned and Implications for Future Trials

EVEREST II 5-Year Report: Beyond the Top-Line Results

Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

Final 5-Year EVEREST II Results: Perspectives on What We Might Have Done Differently

Anatomic Criteria for the MitraClip: Are the Everest Criteria Just a Start?

TCT 788: Outcomes Following Percutaneous Reduction of Significant Mitral Regurgitation in EVEREST II High-Risk Patients Who Were Symptomatic Despite Cardiac Resynchronization Therapy

TCT-85. Ventricular and Atrial Remodeling after the Percutaneous MitraClip: 4 year Follow-up Data from the EVEREST II Randomized Controlled Trial

TCT-89. Percutaneous Leaflet Therapy of Severe Primary Mitral Regurgitation: Totality of Evidence From the EVEREST II Randomized, Continued Access, and High Risk Clinical...

The EVEREST II Randomized Controlled Trial (RCT): Three Year Outcomes

Cost Effectiveness of the MitraClip® Compared with Mitral Valve Surgery: 12-month Results from the EVEREST II Randomized Controlled Trial

Lessons from EVEREST II

Acute and 12-Mo Results with Catheter-Based Mitral Valve Leaflet Repair: EVEREST II High Risk Study

EVEREST II High Surgical Risk Cohort: Clinical Benefit by MR Grade in High Surgical Risk Patients One Year Following MitraClip Therapy.

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content